Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Felix Datlinger, ARVO 2021: Indocyanine Green Angiography-guided Laser Therapy of Teleangiectatic Capillaries

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 3rd 2021

It was a pleasure to catch up with Felix Datlinger (Medical University of Vienna, Vienna, Austria) about his study on functional and morphological long-term outcomes of indocyanine green angiography-guided laser therapy of teleangiectatic capillaries.

Questions

  1. What was previously known about the functional and morphological long-term outcomes of indocyanine green angiography-guided laser therapy of teleangiectatic capillaries? (00:25)
  2. What were the aims and design of the study you are presenting at ARVO? (02:01)
  3. What were the findings of this study and what is their significance for clinical practice? (03:47)

Speaker Disclosure: Felix Datlinger has no financial or non-financial relationships or activities to declare in relation to this interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.

Filmed in coverage of ARVO 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup